MarketsandMarkets analysis says that a Potential Opportunity Worth $50 Bn is opening up in Genomics

 As Genome Sequencing heads to $100 Direct-to-Consumer, a potential opportunity worth $50 Bn is expected to open up, leading to a million terabytes of genome data by 2025.

The genome sequencing market will reach $25 Bn by 2026, further intensified by COVID-19, and oncology and rare disease diagnostics coupled with pan genome studies. Adjacent markets of data storage, high performance computing (HPC), lab automation, and AI are anticipated to see unlocking of a further $20 Bn.

Download PDF Brochure: https://www.marketsandmarkets.com/practices/pdfdownload.asp

According to MarketsandMarkets analysis,

• $50 Bn of potential opportunity is opening up as genome sequencing heads to $100 direct-to-consumer, which was one of the most talked-about trends in 2021.
• The global genomic studies and projects comprising advanced genetic sequencing is expected to drive better clinical decision-making in the coming years, presenting lucrative growth opportunities to NGS companies.
• Additionally, the life sciences market is witnessing an increased adoption of AI, personalized healthcare, gene editing, etc., which is likely to disrupt the demand for genomics, in turn impacting the growth of the market.
• The increasing demand for sequencing and bioinformatics in diagnostics is predicted to disrupt the demand for IVD over the next few years.

MarketsandMarkets is focused on high-growth, niche markets, such as AI in genomics, spatial genomics & transcriptomics, liquid biopsy, single-cell analysis, and related markets, providing a comprehensive understanding of the entire genomics ecosystem through the World’s First Market Intelligence Cloud, ‘KnowledgeStore’. It helps find blind spots in clients’ revenue decisions because of interconnections and unknowns that impacting clients and their client’s clients.

For more details, please visit: https://www.marketsandmarkets.com/practices/genomics-new.asp

Press Release: https://www.marketsandmarkets.com/PressReleases/genomics.asp

Compound Management Market : Size Estimation And Analysis Of Wide Range Of Growth Opportunities For Industry Players

 [118 Pages Report] The Compound management market is projected to reach USD 424.5 million in 2023 from USD 215.3 million in 2018, at a CAGR of 14.5% during the forecast period.

The growth of the market can be attributed to increasing drug discovery activities, the growing biopharmaceutical industry, and the rising trend in outsourcing compound/sample management.

Market Dynamics

• Increasing Drug Discovery Activity
• Growth of the Biopharmaceutical Industry
• Rising Outsourcing of Compound/Sample Management
• Growth of the Biobanking Sector

“By sample type, the chemical compounds segment to account for the largest share during the forecast period.”

The rising drug discovery activity is leading to an increased demand for compounds, which is positively affecting market growth.

Download PDF Brochure @  https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=182172928  

The outsourcing services segment is projected to register the highest CAGR during the forecast period. This high growth is due to the shift in trend towards outsourcing compound management to third-party service providers. These companies are experts in compound management and provide various services to pharmaceuticals, biopharmaceuticals, and CROs with regard to their compound storage needs, and are reasonably priced.

The geographical regions mapped in the report are:1. North America2. Europe3. Asia-Pacific4. Latin America5. Middle East and Africa

The large share of North America is attributed to the presence of the large pharmaceutical and biopharma industry. As a result, several companies in North America are engaged in drug discovery activities, which require the maintenance of substantial chemical libraries. Moreover, to maintain the productivity of such innovative drugs and biologics, most of the leading pharma and biopharma companies have started building compound management facilities or contracting external service providers.

Some key players mentioned in the research report are:

Brooks Automation (US), Hamilton Company (US), TTP Group (US), Labcyte (US), Biosero (US)

Request for sample pages @   https://www.marketsandmarkets.com/requestsampleNew.asp?id=182172928 

Transfer Membrane Market Worth USD 187.9 Million : Indicates Impressive Growth Rate In Pharmaceuticals Industry

 According to the new market research report “ Transfer Membrane Market According to the new market research report “ Transfer Membrane Market by Type (PVDF, Nitrocellulose, Nylon), Transfer Method (Tank, Semi-dry, Dry), Application (Western, Northern, Southern Blot, Protein Sequencing), End user (Academia, Diagnolab, Pharmaceutical Companies)”, published by MarketsandMarkets™,transfer membrane market is projected to reach USD 187.9 million by 2023 from USD 174.8 million in 2018, at a CAGR of 1.5% during the forecast period.

Expected Revenue Growth:

The global transfer membrane market is expected to reach USD 187.9 million by 2023 from USD 174.8 million in 2018, at a CAGR of 1.5% during the forecast period.

Major Growth Drivers:

In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information as well as to assess future prospects.

Factors such as increasing public and private funding for life science research, the significantly high prevalence of target diseases across the globe, and increasing R&D spending by pharmaceutical and biotechnology companies are expected to drive the growth of market.

The report analyzes the global market by type, transfer method, application, end user, and region.

Download PDF Brochure:  https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=36975865

This report covers the market data across four major geographies, namely, North America, Europe, Asia Pacific, and the Rest of the World (RoW). North America is expected to account for the largest share of the global transfer membrane market in 2018, followed by Europe. The large share in the North American region is mainly attributed to the presence of leading transfer membrane manufacturers in the region, availability of government and private financial support for life science research, and high target disease prevalence in the region.

Key Market Players

Thermo Fisher Scientific (US) held the second leadership position in the global market. Other prominent players in the global market included PerkinElmer (US), , Bio-Rad Laboratories (US), GE Healthcare (US), Pall Coporation (US), Advansta (US), GVS (OTCPK), Santa Cruz Biotechnology (US), Abcam (UK), ATTO Corporation (Japan), Carl Roth (Germany), Macherey-Nagel (Germany), Azure Biosystems (US), and Axiva Sichem Biotech (India),.

Request Sample Report:  https://www.marketsandmarkets.com/requestsampleNew.asp?id=36975865

Transplant Diagnostics Market Worth USD 5.5 Billion – Current Status, Growth Dynamics And Future Trends

 According to the new market research report ”Transplant Diagnostics Market by Technology (PCR, NGS, Sanger Sequencing), Product (Instrument, Reagent, Software), Application (HLA, Blood Profile, Pathogen Detection), Type (Heart, Kidney, Liver, Bone Marrow), End User (Hospital) – Global Forecast to 2025“, published by MarketsandMarkets™, transplant diagnostics market is expected to reach USD 5.5 billion by 2025 from USD 3.6 billion in 2019, at a CAGR of 7.2%.

Major Growth Drivers:

The demand for transplant diagnostic products is expected to grow mainly due to factors such as the increasing public-private funding for target research activities, the growing burden of infectious diseases, the increasing number of transplant procedures, and technological advancements in the field of transplant diagnostics.

Expected Revenue Growth:

[227 Pages Report] The transplant diagnostics market is expected to reach USD 5.5 billion by 2025 from USD 3.6 billion in 2019, at a CAGR of 7.2%.

An analysis of the market developments between 2016 and 2019 revealed that product launches & enhancements, partnerships, agreements, and acquisitions were adopted by market players to strengthen their product portfolios and maintain a competitive position in the market. Product launches were the most widely adopted growth strategies.

Download PDF Brochure:   https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=2531061  

The molecular assay technologies segment accounted for the largest share of the transplant diagnostics market, by technology, in 2019

The market, by technology, is segmented into molecular and non-molecular assay technologies. In 2019, the molecular assay technologies segment accounted for the largest share of the market. The large share of this segment can be attributed to the benefits offered by molecular assays such as low turnaround time, high procedural efficacy, the study of multiple samples, and real-time sample analysis.

North America accounted for the largest share of the market in 2019

North America is a well-established market for medical devices. The presence of a highly developed healthcare system, high adoption of innovative transplant diagnostic technologies among medical professionals, the large volume of organ transplantation procedures performed in the region, and technological advancements in the field of transplant diagnostics are the major factors driving the market in North America.

Request for sample pages :   https://www.marketsandmarkets.com/requestsampleNew.asp?id=2531061  

Key Market Players

Some of the players in the transplant diagnostics market are Bio-Rad Laboratories, Inc. (US), Thermo Fisher Scientific Inc. (US), F. Hoffman-La Roche Ltd. (Switzerland), QIAGEN N.V. (Netherlands), bioMérieux SA (France), Immucor, Inc. (US), Becton, Dickinson and Company (US), Merck KGaA (Germany), and Hologic, Inc. (US).

Drug Screening Market : Future Of Chromatography, It Is Creating Real Change In The Rapid Testing Devices Industry

 According to the new market research report ” Drug Screening Market by Product (Consumables, Urine testing devices, Analytical, Breathalyzer, Chromatography) & Services, Sample Type (Urine, Breath), End User (Workplace, Laboratories, Criminal Justice, Hospitals) – Global Forecast to 2025″, published by MarketsandMarkets™ , global drug screening market is projected to reach USD 10.0 billion by 2025, from USD 4.5 billion in 2020, at a CAGR of 17.3%.

Major Growth Drivers:

Growth in this market is attributed to the rising drug & alcohol consumption, the enforcement of stringent laws mandating drug and alcohol testing, government funding in major markets, and regulatory approvals and product and service launches.

Expected Revenue Growth:

[192 Pages Report] The global drug screening market is projected to reach USD 10.0 billion by 2025, from USD 4.5 billion in 2020, at a CAGR of 17.3%.

COVID-19 impact on the drug screening market

COVID-19 has resulted in significant disruptions to businesses and economic activities globally and is expected to have a short-term negative impact on the drug screening market due to limited or non-availability of medical facilities/treatment centers, harm reduction service providers, and the fear of infection transmission. To reduce the strain on the healthcare system and decrease disease transmission, various governments worldwide provided guidelines to postpone or delay non-essential medical and surgical procedures.

Browse in-depth TOC on “Drug Screening Market”192 – Tables35 – Figures192 – Pages

Download PDF Brochure: Drug Screening Market

The rapid testing devices segment will witness the highest growth during the forecast period.

Based on product, the drug screening market is segmented into analytical instruments, rapid testing devices, and consumables. Rapid testing devices market is further subsegmented into urine testing devices and oral fluid testing devices. The urine testing devices segment is expected to account for the largest market share in 2019. However, the oral fluid testing devices segment is projected to register highest CAGR during the forecast period. The high growth in this segment is attributed to the benefits it offers such as shorter detection window, non-invasive nature, and low risk of sample tampering.

North America was the largest regional market for drug screening market in 2019.

The drug screening market is segmented into North America, Europe, the Asia Pacific, and the Rest of the World. In 2019, North America was the largest regional segment of the overall market, followed by Europe. The dominance of the North American market is attributed to factors such as rising consumption of illicit drugs, availability of government funding to curb drug abuse, and the presence of laws supporting drug screening, and growing burden of accidents due to unsafe levels of alcohol consumption.

Request for sample pages : Drug Screening Market

Key Market Players

The prominent players operating in this market include LabCorp (US), Quest Diagnostics (US), Alere (US), OraSure (US), Alfa Scientific Designs (US), Thermo Fisher Scientific (US), Drägerwerk (Germany), LifeLoc (US), MPD Inc. (US), Omega Laboratories (US), Premier Biotech (US), Psychemedics (US), Roche (Switzerland), Shimadzu (Japan), and Siemens Healthineers (Germany).

Synthetic Biology Market To Reach USD 30.7 Billion By 2026 – Scope In Gene Synthesis

According to the new market research report “Synthetic Biology Market by Tools (Oligonucleotides, Enzymes, Synthetic Cells), Technology (Gene Synthesis, Genome Engineering), Application (Tissue Regeneration, Biofuel, Consumer Care, Food & Agriculture, Environmental) and Region – Global Forecast to 2026″, published by MarketsandMarkets™, the global market size is projected to reach USD 30.7 billion by 2026 from USD 9.5 billion in 2021, at a CAGR of 26.5% during the forecast period.

Browse in-depth TOC on “Synthetic Biology Market”452 – Tables39 – Figures377 – Pages

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=889

COVID-19 impact on the synthetic biology market

Many established pharmaceutical and biopharmaceutical companies, along with players of the synthetic biology market, have stepped forward to contribute to worldwide research efforts by providing synthetic biology for developing test kits, treatments, and vaccines to target the infection caused by the coronavirus. Synthetic biology is highlighted as one of the emerging technologies in a report from the European Parliament. It can fight the COVID-19 pandemic. The National Institute of Health in the US has also identified synthetic biology as one way to speed up vaccine development.

The medical applications segment accounted for the largest share of the application segment in the market in 2020.

Based on application, the market is categorized into three segments—medical applications, industrial applications, food & agriculture, and environmental applications. In 2020, medical applications segment accounted for the largest share of synthetic biology market. Factors such as the extensive research on new and better treatments, coupled with the availability of huge private and public funding for the discovery of novel therapies, is the primary driver for the medical segment’s growth.

Request for sample pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=889

The Asia Pacific region is the fastest-growing region of the synthetic biology market in2020.

The Asia Pacific region is estimated to grow at the highest CAGR in the market during the forecast period, this is mainly due to factors such the growing collaborations in the field of synthetic biology, growing partnerships in the Chinese market, and investments in Asia Pacific countries for research.

IV Equipment Market – By 2022, Global Industry Is Expecting To Grow At CAGR Of 6.2%

 Intravenous (IV) therapy devices are used to administer liquid substances directly into a vein. They can deliver nutrients or medications such as insulin or other hormones, antibiotics, chemotherapy drugs, and pain relievers. Presently, many companies are developing various infusion devices capable of being integrated with alarm devices, monitoring devices, and data exchange systems.  

[166 Pages Report] The overall IV equipment market is expected to grow from USD 10.07 billion in 2017 to USD 13.64 billion by 2022, at a CAGR of 6.2% from 2017 to 2022.

The global burden of chronic diseases such as heart disease, stroke, cancer, chronic respiratory diseases, and diabetes is increasing rapidly. According to the World Health Organization (WHO) 2015, chronic diseases accounted for approximately 60% of the total reported deaths in the world. The proportion of the burden of chronic diseases (chronic non-communicable diseases) is expected to increase to 57% by 2020 from 46% in 2001.

Market Dynamics

1. Low Prices of Reprocessed Medical Devices2. Pressure to Reduce Volume of Regulated Medical Waste

Increasing incidence of chronic diseases and rising geriatric population, growing number of surgical procedures performed, rising demand for ambulatory infusion pumps due to the growing home care market, rising number of needlestick injuries and infections are the key factors driving the growth of this market

Download PDF Brochure @  https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=78345313 

The geographical regions mapped in the report are:1. North America2. Europe3. Asia-Pacific4. Middle East and Africa5. Latin America

The IV equipment market in APAC is expected to grow at the highest CAGR during the forecast period. The demand for IV equipment and accessories in the APAC region is majorly driven by factors such as the large population base in the region, rising geriatric population, rising incidence of chronic diseases, improving accessibility to advanced healthcare facilities, rising healthcare spending, growing penetration of health insurance, increasing demand for advanced technologies, growing investments in emerging APAC countries by key market players, and expansion of private-sector hospitals to rural areas.

Some key players mentioned in the research report are:

Some of the prominent players in the global IV equipment market are Becton, Dickinson and Company (U.S.), B. Braun Melsungen AG (Germany), Baxter Interanl Inc. (U.S.), Fresenius SE & Co. KGaA (Germany), ICU Medical, Inc. (U.S.), Smiths Medical (U.K.), C. R. Bard, Inc. (U.S.), Terumo Corporation (Japan), Moog, Inc. (U.S.), and AngioDynamics, Inc. (U.S.). These players adopted both organic as well as inorganic strategies such as product launches and enhancements, collaborations and agreements, acquisitions and grant to sustain in this market.